Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stem cell secretome (Universitas Sebelas Maret)
- Development stage
- Unknown
- Lead developer
- Universitas Sebelas Maret
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Mesenchymal stem cell (MSC) secretome is an investigational cell-free biologic therapy being developed by Universitas Sebelas Maret in collaboration with Kalbe Farma for the treatment of rheumatoid arthritis. Derived from the bioactive factors secreted by MSCs—typically umbilical cord-derived—the secretome contains a complex mixture of cytokines, growth factors, and extracellular vesicles (including exosomes). It functions by modulating the immune system and exerting anti-inflammatory effects, offering a potentially safer and more standardized alternative to direct stem cell transplantation. The therapy is currently being evaluated in Phase 1/2 clinical trials to assess its safety and efficacy in reducing joint inflammation and disease activity in patients with rheumatoid arthritis.
- Other names
- MSC secretomeMessenchymal stem cell secretome
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)TGFBR (TGF-beta receptor)IL-6R (Interleukin-6 receptor subunit alpha)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on mesenchymal stem cell secretome (Universitas Sebelas Maret).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stem cell secretome (Universitas Sebelas Maret).